AR
ARWR.US Arrowhead Pharmaceuticals Inc
- Market cap
- USD 6.75B
- P/E
- -
- P/B
- 14.31x
- ROE
- -1,439.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is ARWR.US undervalued?
Graham numberThe Graham number of Arrowhead Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arrowhead Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Arrowhead Pharmaceuticals Inc yet.
Arrowhead Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also …
Full company profileArrowhead Pharmaceuticals Inc financial statements
Arrowhead Pharmaceuticals Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 31.4M | 16.1M | 169M | 88.0M | 138M | 243M | 241M | 3.55M | 829M | 451M |
| Gross Profit | 31.4M | 16.1M | 169M | 88.0M | 138M | 243M | 228M | -15.0M | 829M | 449M |
| Operating Income | -37.0M | -55.9M | 61.2M | -93.2M | -149M | -179M | -205M | -601M | 98.3M | -707M |
| EBITDA | -32.3M | -51.2M | 65.6M | -87.2M | -133M | -168M | -176M | -562M | 165M | -604M |
| Net Income | -34.4M | -54.5M | 68.0M | -84.6M | -141M | -176M | -205M | -599M | -1.63M | -724M |
| EPS | -0.47 | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 | -5.11 |
| Balance Sheet | ||||||||||
| Total Assets | 104M | 112M | 350M | 523M | 710M | 692M | 766M | 1.14B | 1.39B | 1.74B |
| Total Liabilities | 23.2M | 16.4M | 106M | 60.7M | 301M | 274M | 478M | 949M | 882M | 1.69B |
| Shareholders' Equity | 81.4M | 95.8M | 245M | 462M | 409M | 399M | 271M | 185M | 466M | 50.3M |
| Cash & Short-term Investments | 65.6M | 76.5M | 259M | 315M | 368M | 376M | 404M | 681M | 919M | 1.19B |
| Total Debt | 2.53M | 2.33M | - | 21.1M | 25.5M | 81.6M | 383M | 852M | 366M | 1.00B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -23.9M | -47.2M | 173M | -95.8M | 171M | -136M | -154M | -463M | 180M | -272M |
| Capital Expenditure | 7.92M | 1.42M | 12.0M | 12.0M | 23.6M | 52.8M | 177M | 141M | 22.7M | 12.0M |
| Free Cash Flow | -31.9M | -48.6M | 161M | -108M | 148M | -189M | -331M | -604M | 157M | -284M |
| Ratios | ||||||||||
| ROE | -42.2% | -56.8% | 27.8% | -18.3% | -34.5% | -44.3% | -75.7% | -323.3% | -0.3% | -1,439.4% |
| ROA | -33.1% | -48.8% | 19.4% | -16.2% | -19.8% | -25.5% | -26.8% | -52.6% | -0.1% | -41.7% |
| Net Profit Margin | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.6% | -85.3% | -16,882.4% | -0.2% | -160.6% |
| Debt to Equity | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.41x | 4.59x | 0.79x | 19.88x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arrowhead Pharmaceuticals Inc dividends
Arrowhead Pharmaceuticals Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Nov 17, 2011.
Who owns Arrowhead Pharmaceuticals Inc
- Insiders 3.66%
- Institutions 85.91%
- Public & others 10.44%
- Shares outstanding 141M
- Free float 123M
Top funds holding ARWR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 5.08M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.27M | 3.02% | +0.27% | Sep 2026 |
| Vanguard Small Cap Index | 3.02M | 2.14% | -1.88% | Sep 2026 |
| Fidelity Growth Company Fund | 2.60M | 1.84% | +2.01% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.92M | 1.36% | +2.68% | Oct 2026 |
| Invesco S&P MidCap Momentum ETF | 1.81M | 1.28% | -0.06% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.68M | 1.19% | -4.80% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 1.04M | 0.74% | +1.39% | Sep 2026 |
| iShares Biotechnology ETF | 1.03M | 0.73% | -0.37% | Oct 2026 |
| Invesco Discovery A | 980K | 0.69% | +4.28% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 850K | 0.60% | -0.26% | Oct 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 768K | 0.54% | +0.05% | Oct 2026 |
| Alger Focus Equity I | 763K | 0.54% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 750K | 0.53% | +0.24% | Oct 2026 |
| Fidelity Growth Company K6 | 745K | 0.53% | +2.00% | Aug 2026 |
| Fidelity Extended Market Index | 646K | 0.46% | -5.70% | Sep 2026 |
| Fidelity Series Growth Company | 618K | 0.44% | +1.01% | Aug 2026 |
| iShares Russell Mid-Cap ETF | 574K | 0.41% | -0.06% | Oct 2026 |
| Hood River Small-Cap Growth Instl | 572K | 0.40% | -1.12% | Jun 2026 |
| Fidelity Mid Cap Index | 511K | 0.36% | -0.60% | Sep 2026 |
Top institutions holding ARWR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 14.8M | 10.50% | -18.34% | Jun 2026 |
| venBio Select Advisor LLC | 11.4M | 8.04% | +6.13% | Jun 2026 |
| FMR Inc | 8.04M | 5.69% | +10.64% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.35M | 4.50% | -11.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.11M | 4.33% | +1.30% | Jun 2026 |
| State Street Corp | 5.69M | 4.03% | -12.34% | Jun 2026 |
| NORGES BANK | 3.90M | 2.76% | +128.61% | Jun 2026 |
| Amvescap Plc. | 3.88M | 2.75% | +18.39% | Jun 2026 |
| Geode Capital Management, LLC | 3.53M | 2.50% | -17.49% | Jun 2026 |
| Fred Alger Management, LLC | 3.30M | 2.34% | -1.21% | Jun 2026 |
| Baker Bros Advisors LP | 1.99M | 1.41% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 1.72M | 1.21% | +6.19% | Jun 2026 |
| Vestal Point Capital LP | 1.58M | 1.12% | -30.77% | Jun 2026 |
| Deerfield Management Co | 1.39M | 0.98% | -11.71% | Jun 2026 |
| First Trust Advisors L.P. | 1.35M | 0.96% | +807.10% | Jun 2026 |
| Driehaus Capital Management LLC | 1.35M | 0.96% | +13.46% | Jun 2026 |
| Jupiter Topco LLC | 1.22M | 0.86% | 0.00% | Jun 2026 |
| Northern Trust Corp | 1.19M | 0.84% | -27.96% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.15M | 0.81% | -33.90% | Jun 2026 |
| Bank of America Corp | 1.14M | 0.81% | +7.08% | Jun 2026 |
Arrowhead Pharmaceuticals Inc company profile
- Company name
- Arrowhead Pharmaceuticals Inc
- Ticker
- ARWR.US
- Exchange
- USA Stocks
- Listed since
- Jun 16, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 711
- Fiscal year end
- September
- Address
- 177 East Colorado Boulevard, Pasadena, CA, United States, 91105
- Phone
- 626 304 3400
- Website
- arrowheadpharma.com
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals Inc management
10- Dr. Christopher R. Anzalone Ph.D.Chairman, CEO & President · born 1969
- Mr. Daniel J. ApelChief Financial Officer · born 1966
- Mr. Patrick O'Brien J.D., PharmDCOO & Secretary · born 1964
- Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of R&D · born 1979
- Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & Calando
- Dr. Tao Pei Ph.D.Chief Scientific Officer
- Dr. Vincent Anzalone CFAHead of Investor Relations & VP
- Mr. Howard LovyDirector of Communications
- Dr. Bruce D. Given M.D.Chief Medical Scientist · born 1954
- Dr. Mark SeefeldHead of Toxicology & VP · born 1954